Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
FAQs
Advertise
UsernamePublicRestriction
Tags:
Approvals Ophthalmic Market Intelligence

Regeneron Gets A Win With Eylea Approval In Diabetic Retinopathy

  • News

Executive Summary

Regeneron's workhorse blockbuster Eylea has scored another indication for diabetic retinopathy, as the company braces for new competition from Novartis later this year.

You may also be interested in...



PANORAMA Helps Regeneron's Eylea Even Score With Roche's Lucentis

Phase III PANORAMA looks good, so far, for Regeneron's Eylea in diabetic retinopathy without edema.

Keeping Track: US FDA Expands Indications For Roche Tecentriq, Lucentis, Approves Second Infliximab Biosimilar

The latest drug development news and highlights from our FDA Performance Tracker.

Why Is Congress Targeting These Six Medicines In Drug Price Hearing?

Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.

Table

View full table

Topics

Related Companies

Tags:
Approvals Ophthalmic Market Intelligence
UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By